NCT03380962 - Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2025

Conditions

Kidney Failure, ChronicEnd-Stage Renal DiseaseTransplant GlomerulopathyTransplant;Failure,KidneyKidney Transplant Failure and RejectionAntibody-mediated RejectionKidney Transplant; Complications

Interventions

DRUG

Clazakizumab

All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.

Trial Locations (1)

90048

Norko Ammerman, Los Angeles

All Listed Sponsors

lead

Stanley Jordan, MD

OTHER